Título : SARS-CoV-2 Infection in Multiple Sclerosis. Results of the Spanish Neurology Society Registry |
Autor : Arrambide, Georgina Llaneza-González, Miguel Ángel Costa-Frossard França, Lucienne Meca-Lallana, Virginia Fernández- Díaz, Eva Moreno Torres, Irene García-Domínguez, Jose Manuel Ortega Suero, Gloria Ayuso-Peralta, Lucia Gomez-Moreno, Mayra Sotoca-Fernández, Javier J. Caminero-Rodríguez, Ana Belén Rodríguez de Antonio, Luis A. Corujo-Suárez, Marcial Otano-Martínez, María A. Pérez-Miralles, Francisco Carlos Reyes-Garrido, Virginia Ayuso-Blanco, Teresa Balseiro-Gómez, José Jesús Muñoz Pasadas, Mercedes Pérez-Molina, Inmaculada Arnal-García, Carmen Domingo-Santos, Angela Guijarro-Castro, Cristina Íñiguez-Martínez, Cristina Téllez Lara, Nieves Castellanos Pinedo, Fernando Castillo-Trivino, Tamara Cerdán-Santacruz, Debora María Perez-Sempere, Angel Sebastián Torres, Berta Álvarez de Arcaya, Amaya Costa-Arpín, Eva Durán-Ferreras, Eduardo Fragoso-Martínez, Marta González Platas, Montserrat Landete, Lamberto Millán-Pascual, Jorge Oreja-Guevara, Celia MECA-LALLANA, JOSE EUSTASIO |
Editor : Wolters Kluwer Health/Lippincott Williams & Wilkins |
Departamento: Departamentos de la UMH::Medicina Clínica |
Fecha de publicación: 2021 |
URI : https://hdl.handle.net/11000/33767 |
Resumen :
Objective
To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify
high-risk individuals due to their immunocompromised state resulting from the use of diseasemodifying
treatments.
Methods
Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome.
Results
Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04–1.17) as the only independent risk factor for a fatal outcome.
Conclusions
This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.
|
Palabras clave/Materias: Esclerosis múltiple COVID-19 |
Área de conocimiento : CDU: Ciencias aplicadas: Medicina |
Tipo documento : application/pdf |
Derechos de acceso: info:eu-repo/semantics/openAccess |
DOI : https://doi.org/10.1212/NXI.0000000000001024 |
Aparece en las colecciones: Artículos Medicina Clínica
|